Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial
Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.
You may also be interested in...
Sanofi has received a go-ahead in India for dupilumab in atopic dermatitis with a trial waiver. An India-specific price, local real-world effectiveness and safety study and compelling data are expected to give it an edge over competition in the wings, including Pfizer’s Cibinq.
Sanofi is looking to build its position in immunology, with a new anti-inflammatory candidate, amlitelimab, which could potentially help patients who do not respond to its blockbuster Dupixent.
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.